Simulations Plus board authorizes renewed share repurchase program

Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of simulation and modeling software for pharmaceutical discovery and development, announced today that its board of directors has authorized a renewed share repurchase program effective Monday, February 15, 2010.

Ms. Momoko Beran, chief financial officer of Simulations Plus, said: “The board of directors has decided to restart our share repurchase program, enabling the buyback of up to one million shares during a 12-month period beginning Monday, February 15, 2010. Repurchases may be made in the open market, through a broker, or through privately negotiated transactions, subject to market conditions, applicable legal requirements and other factors. Simulations Plus has no obligation to repurchase shares under the repurchase program and the timing, actual number, and price of shares to be purchased will depend on the performance of Simulations Plus' stock price, general market conditions, and various other factors. Such purchases, if any, will be made in accordance with applicable insider trading and other securities laws and regulations within the discretion of management.”

Walt Woltosz, chairman and chief executive officer of Simulations Plus, added: “At this time, the board believes that the continued undervaluation of our stock and the continued growth of our cash, warrants continuing the share repurchase program we had during December 2008 to December 2009, subject to management’s discretion and market conditions as Ms. Beran has described. Authorizing this amount is not expected to interfere with potential acquisitions or with meeting operating requirements, which the board believes are of utmost priority.”

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Writing by hand enhances brain function critical for learning